You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in the Czech Republic

Apr 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Consumer health hampered by worse economic situation

As in other fmcg, consumer health was negatively influenced by the poor economic situation at the end of the review period. After the outbreak of the financial crisis, consumers started to be more careful with their money and reduced their expenses, especially on more expensive and non-essential products. Within consumer health this attitude was proved by the decrease in the growth rate in 2009 and by the drop in value sales in 2010. Although current value sales of consumer health grew again in 2011, the increase was moderate. Nevertheless, consumer health was not impacted by worsened economic situation as strongly as some other product areas due to the fact that consumer health products are considered essential.

Consumers economise in order to reduce their expenses

On-going poor economic situation and the connected uncertainty among consumers brought some changes in customer behaviour at the end of the review period. Firstly, consumers thought more about their purchases and tended to buy products that they really needed, and secondly, many consumers became more economical in their consumption and purchases. Within consumer health, these changes were seen in the increased demand for products sold in higher pack sizes which offered more advantageous prices. Furthermore, consumer health products were also purchased less frequently as reserves by many consumers.

Zentiva, followed by domestic company Walmark, leads sales in 2011

Consumer health was led by Zentiva ks, followed by domestic company Walmark in 2011. Other leading players within consumer health were GlaxoSmithKline sro, Teva Czech Industries sro and domestic company Green Swan Pharmaceuticals CR as. Although multinationals led sales of OTC products, two domestic companies, namely Walmark and Green Swan Pharmaceuticals, dominated sales of vitamins and dietary supplements in 2011. The success of these leading players lies in their well-established brands which enjoy consumer trust in terms of quality and safety.

Chemists/pharmacies remains most important distribution channel

As chemists/pharmacies is traditional channel for sales of consumer health products and offers the widest range of these products, it remained the most important distribution channel within consumer health in 2011. Nevertheless, the value share of pharmacies gradually decreased over the review period and this trend is predicted to persist over the forecast period. Traditional pharmacies is expected to lose ground in favour of other channels, such as modern grocery retailers and parapharmacies/drugstores as these channels are expected to continue their expansion over the forecast period. However, the biggest improver in value share is expected to be internet retailing (online pharmacies) as popularity of online shopping is growing strongly among Czech consumers.

Consumer health is predicted to see satisfactory growth over the forecast period

It is expected that consumer health will see more dynamic growth in constant value terms over the forecast period than during the review period. Sales will be driven by growing interest in prevention and self-medication as well as by modern hectic lifestyles and worsening environment over the forecast period. Furthermore, value sales of consumer health products will be boosted by price increases at the beginning of the forecast period as the advantageous VAT rate will increase from 10% to 14% in 2012 and to 17.5% in 2013.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Czech Republic with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Czech Republic, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Czech Republic for free:

The Consumer Health in Czech Republic market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Czech Republic?
  • What are the major brands in Czech Republic?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in the Czech Republic - Industry Overview

EXECUTIVE SUMMARY

Consumer health hampered by worse economic situation

Consumers economise in order to reduce their expenses

Zentiva, followed by domestic company Walmark, leads sales in 2011

Chemists/pharmacies remains most important distribution channel

Consumer health is predicted to see satisfactory growth over the forecast period

KEY TRENDS AND DEVELOPMENTS

Ongoing poor economic situation negatively impacts sales of consumer health products

All leading producers maintain their value shares in 2011

Private label products remain limited

Chemists/pharmacies remains a key distribution channel

Lifestyle, growing interest in self-medication, prevention and rising health awareness are main drivers of sales of consumer health

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Penetration of Private Label by Category 2006-2011
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventative medicine

Switches

  • Summary 1 OTC Switches 2009-2011

DEFINITIONS

SOURCES

  • Summary 2 Research Sources

Consumer Health in the Czech Republic - Company Profiles

Green Swan Pharmaceuticals CR as in Consumer Health (Czech Republic)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 4 Green Swan Pharmaceuticals CR as: Competitive Position 2011

Profarma Produkt sro in Consumer Health (Czech Republic)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 6 Profarma Produkt sro: Competitive Position 2011

Vitar sro in Consumer Health (Czech Republic)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Vitar sro: Competitive Position 2011

Walmark as in Consumer Health (Czech Republic)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 10 Walmark as: Competitive Position 2011

Zentiva ks in Consumer Health (Czech Republic)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 12 Zentiva ks: Competitive Position 2011

Adult Mouth Care in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • The healthy growth in adult mouth care over the review period slowed down in 2009 and stopped in 2010 due to the negative impacts of the poor economic situation when consumers reduced their expenses. As this attitude continued in 2011, adult mouth care had only moderate value growth of 1%. Adult mouth care is niche, with sales of CZK89 million in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • Adult mouth care was led by GlaxoSmithKline, closely followed by Aura Medical with 21% value share each in 2011. Other successful players within adult mouth care included Teva Czech Industries with 16% value share in 2011, Zentiva with 11% value share, Mundipharma with 5% value share and STADA Arzneimittel with 3% value share in 2011.

PROSPECTS

  • Adult mouth care is expected to have constant value growth of 6% over the forecast period. This moderate but stable growth will be driven by rising health awareness of Czech consumers and their increased focus on preventing illness and other health complaints. Adult mouth care will remain niche with sales of CZK95 million in 2016.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2006-2011
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 14 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 15 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Analgesics is one of the highest and most dynamic categories within OTC in the Czech Republic. Its products provide a good solution of quick and easy pain relief. Analgesics products are very prevalent in the country and are common part of medicine chest cabinets in most of Czech households. In majority of cases, these medicines are used to relive common pain such as headaches, period pain and other conditions that do not require consultation with a doctor. Moreover, introduction of regulatory fees (for a visit to the doctor and every prescription item) in 2008 supported sales of analgesics at the end of the review period.

SWITCHES

COMPETITIVE LANDSCAPE

  • Zentiva remained leader of analgesics with a 20% value share in 2011. The company offers wide range of well-known and well-established products and enjoys strong consumer loyalty and trust thanks to its long presence on the Czech market. The company led sales of acetaminophen, ibuprofen, paediatric ibuprofen and topical analgesics/anaesthetic and was second in paediatric acetaminophen in 2011. Zentiva’s most popular analgesics brands include Ibalgin and Paralen which are perceived as synonymous with analgesics by some Czechs.

PROSPECTS

  • Analgesics is expected to see healthy growth of 22% in constant value sales over the forecast period. Sales will be driven by growing consumption due to increasingly hectic lifestyles and growing interest in self-medication over the forecast period. Moreover, it is expected that sales of analgesics will be supported by rising demand for more sophisticated products which will be able to offer added value. In general, analgesics products are, and will continue to be, one of the basic items present in nearly every household as these products are used to alleviate the symptoms of all types of pain and also reduce fever.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2006-2011
  • Table 19 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 21 Analgesics Company Shares by Value 2007-2011
  • Table 22 Analgesics Brand Shares by Value 2008-2011
  • Table 23 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Calming and sleeping had moderate value growth of 1% in 2011. This growth was higher compared to 2009 and 2010, however it was lower than pre-financial crisis performance. This was because consumers retained their restrained attitude in 2011. Calming and sleeping is niche with sales of CZK77 million in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • Both multinationals and domestic companies are present in calming and sleeping. Nevertheless, two multinationals led sales in 2011: Sandoz with 28% value share (brand Persen) and Teva Czech Industries with 27% value share (brand Novo-Passit). The success of these companies lies in their well-established brands. Both products, Persen and Novo-Passit, have a wide range of effects as they are intended for treatment of anxiety, mental strain, aggravation or moodiness, but can be used also for treatment of sleeping disorders.

PROSPECTS

  • Calming and sleeping is expected to have constant value growth of 8% over the forecast period, which is a faster pace than the growth seen over the review period. Sales of calming and sleeping will be driven by hectic and stressful lifestyles. It is expected that a higher number of people will be exposed to stress and fast-paced lifestyles which will result in an increased number of people suffering from depression, anxiety or sleeping disorders. Moreover, OTC calming and sleeping products are expected to be more popular at the expense of prescription products as they are considered to be healthier and safer.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2006-2011
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 27 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 28 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Cough, cold and allergy remedies had the highest value in OTC with CZK2.7 billion in 2011. Cold and flu are common illnesses and many consumers prefer self-medication to visiting a doctor when symptoms are not very serious. This also fits with the lifestyle in 2011, when some people are not willing to stay at home when they fell ill with cold and flu. Sales of cough, cold and allergy remedies are dependent on weather conditions which determine the intensity and frequency of incidences of cold and flu.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline led sales of cough, cold and allergy remedies with a 12% value share in 2011. The success of the company lies in its popular brand Coldrex which was leading brand of cough, cold and allergy remedies, with 12% value share in 2011. Coldrex is well-known among Czech consumers thanks to strong promotion and advertising during the review period. The company offers several brand variants of Coldrex, including Coldrex, Coldrex Nite and Coldrex HotRem (combination products), Coldrex Broncho Syrup (cough remedies) and Coldrex Proti Bolesti v Krku (Pharyngeal preparations). GlaxoSmithKline had the highest success in combination products where it was clear leader with 40% value share in 2011.

PROSPECTS

  • Cough, cold and allergy remedies is predicted to have constant value growth of 17% over the forecast period, which is faster than review period growth. The fast-paced and hectic lifestyle of Czechs together with worsening environment will drive sales of these remedies. It is also expected that more consumers will prefer self-medication as this is the fastest and simplest way of treating cold and flu symptoms. Finally, demand for these remedies will also be fuelled by wide offer of products sold in different formats and in all price categories.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 33 Sales of Decongestants by Category: Value 2006-2011
  • Table 34 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 36 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Digestive remedies had value growth of 1% in 2011 which was only slightly lower compared to review period value CAGR. Sales of digestive remedies were driven by lifestyle and bad eating habits of many Czechs. Moreover, many consumers preferred to buy OTC medicines to cure digestive ailments (on the base of pharmacist advice) rather than visiting a doctor (in case the complaint was not serious or long-running). Nevertheless, the stable rate of value growth which was had over the review period decreased towards the end of this period due to lower consumer spending in times of worsened economic conditions.

SWITCHES

COMPETITIVE LANDSCAPE

  • Zentiva ks remained leader of digestive remedies with 10% value share in 2011. The company is well-known and well-established among Czech consumers thanks to its long-standing presence on the market. Moreover, company’s brands enjoy strong consumer loyalty and trust and are considered to be quality and sold at affordable prices. Zentiva ks had the highest success in diarrhoeal remedies and proton pump inhibitors where it was first and was present in digestive enzymes and laxatives. The most successful company’s brand Endiaron was leading brand of digestive remedies with value share of 6% in 2011. This diarrhoeal remedy has very long presence on the Czech market and thus enjoys strong consumer loyalty and trust.

PROSPECTS

  • Digestive remedies is expected to see stable growth with constant value CAGR of 2% over the forecast period. Sales will be driven by the fact that diet-related illnesses will remain common due to fast-paced lifestyle and unhealthy eating habits of many Czechs. Although Czech consumers are increasingly aware of importance of a balanced diet, many of them are not willing to change their eating habits. Moreover, it is expected that lifestyle of many Czechs will be faster with more stress and lack of leisure time over the forecast period.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 43 Digestive Remedies Company Shares by Value 2007-2011
  • Table 44 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Ear care is a niche market, with retail value sales of CZK13 million in 2011. Although ear care had dynamic growth at the beginning of the review period, the financial crisis, which resulted in lower disposable incomes of many consumers, hampered growth in 2009 and caused a decrease in sales in 2010. As the poor economic situation persisted in 2011, ear care had moderate growth of 1% in this year.

SWITCHES

COMPETITIVE LANDSCAPE

  • Ear care is dominated by two multinationals, Laboratoires Diepharm and Herb-Pharma. The leader, Laboratoires Diepharm, had 58% value share in 2011 with its brand Audispray, while Herb-Pharma held 38% value share in 2011 with brand Aurecon. Both these brands are popular for their convenient and easy use and immediate effect. There are also available variants for children older than six months within these two brands.

PROSPECTS

  • Ear care is expected to see moderate but stable growth with constant value CAGR of 1% over the forecast period. Sales will be driven by rising health awareness among Czech consumers and their more conscientious attitude to prevention as a tool in order to prevent more serious health complaints.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2006-2011
  • Table 48 Sales of Ear Care: % Value Growth 2006-2011
  • Table 49 Ear Care Company Shares by Value 2007-2011
  • Table 50 Ear Care Brand Shares by Value 2008-2011
  • Table 51 Forecast Sales of Ear Care: Value 2011-2016
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2011-2016

Emergency Contraception in the Czech Republic - Category Analysis

TRENDS

  • Some emergency contraception products were switched from Rx to OTC with restriction status at the end of November 2011. OTC with restriction status means that only one pack of emergency contraception can be sold (en bloc) to women over 16 years and the pharmacist has a duty to register information about dispensation of emergency contraception products.

Eye Care in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Sales of eye care were supported by worsening environment together with lifestyle of Czechs in 2011. Long periods of time in front of TV and computers, driving, smog and dust, all had negative impact on eyes. They contributed to incidences of complaints such as eye irritation, dryness, redness, itching or burning. Furthermore, increasingly higher pollution of environment contributed to more frequent incidence of eye allergies.

SWITCHES

COMPETITIVE LANDSCAPE

  • Eye care is dominated by two successful players: Teva Czech Industries with 40% value share in 2011, closely followed by Zentiva with 38% value share. The third successful player within eye care was Johnson & Johnson with 14% value share.

PROSPECTS

  • Eye care is expected to have constant value growth of 14% over the forecast period which is a faster rate than growth in the review period. Sales will be driven by similar trends as over the review period, ie by worsening environment together with consumer lifestyle. Eye care is expected to reach sales of CZK161 million by 2016.

CATEGORY DATA

  • Table 53 Sales of Eye Care by Category: Value 2006-2011
  • Table 54 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 55 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 56 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 57 Eye Care Company Shares by Value 2007-2011
  • Table 58 Eye Care Brand Shares by Value 2008-2011
  • Table 59 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 60 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Herbal/traditional products has value growth of 2% in 2011. This performance was lower compared to review period CAGR as consumers were more careful with money due to worsened economic situation and lower disposable incomes at the end of the review period. Herbal/traditional products reached sales of CZK1 billion in 2011.

COMPETITIVE LANDSCAPE

  • Herbal/traditional products was led by Ed Haas CZ with 23% value share in 2011. The company led sales of herbal/traditional cough, cold and allergy remedies where it offers popular medicated confectionery brands Halls and Vita-C. The success of the company is due to the popularity of brand Halls which was leading brand of herbal/traditional products, with 19% value share in 2011.

PROSPECTS

  • Herbal/traditional products is expected to have constant value growth of 14% over the forecast period, which is a faster pace than the growth seen over the review period. Sales will be driven by health and wellness trends and growing popularity of herbal products. It is expected that rising number of consumers will prefer products with natural origin as these products are considered to be beneficial to health and to be safe thanks to minimum of side effects.

CATEGORY DATA

  • Table 61 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 62 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 63 Herbal/Traditional Products Company Shares 2007-2011
  • Table 64 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 65 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 66 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Sales of medicated skin care over the review period were driven by hectic lifestyle and worsening environment which brought negative repercussions on health of consumers, such as skin ailments, haemorrhoids and allergies. Furthermore, higher emphasis on physical appearance also supported sales of medicated skin care as many skin ailments are visible and thus socially unpleasant.

SWITCHES

COMPETITIVE LANDSCAPE

  • Medicated skin care was led by Bayer with 12% value share in 2011. The company led sales of vaginal antifungals, was second in topical antifungals and nappy (diaper) rash treatments and fifth in topical germicidals/antiseptics. Bayer's successful brands include topical and vaginal antifungals Canesten, nappy rash treatment Bepanthen and topical antiseptic Bepanthen Plus.

PROSPECTS

  • Medicated skin care is expected to have 9% constant value growth over the forecast period. The main drivers of sales of medicated skin care are expected to remain the same as over the review period – worsening environment and fast-paced lifestyle which cause growing number of incidences of skin complaints. Besides, value growth of medicated skin care is also expected to be supported by rising demand for more sophisticated, high quality and effective products over the forecast period.

CATEGORY DATA

  • Table 67 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 68 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 69 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 70 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 71 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 72 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 73 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • NRT smoking cessation aids had only marginal value growth of 1% in 2011 to reach CZK83 million. Although quitting smoking is one of the most effective ways of reducing household expenses, NRT smoking cessation aids is an expensive way to do this and thus these products put pressure on family budgets in poor economic times. As a result, value sales had a slower growth rate in 2009 and value decline in 2010. In 2011, value sales of NRT smoking cessation aids showed growth again, but only moderate as consumers continued to save on expensive and non-essential products in this year.

SWITCHES

COMPETITIVE LANDSCAPE

  • NRT smoking cessation aids is niche with only two multinational players present on the Czech market in 2011: Johnson & Johnson with brand Nicorette and GlaxoSmithKline with brand Niquitin. The third player, Novartis, which offered brand Nicotinell, withdrew from the Czech NRT smoking cessation aids market in 2009.

PROSPECTS

  • It is expected that NRT smoking cessation aids will register value growth of 7% over the forecast period. Sales will be driven by rising health awareness among Czechs as more people will try to quit smoking. Moreover, value sales of NRT smoking cessation aids will be supported by moderate growth of price of these products due to increase of VAT rate in 2012 and 2013. It is expected that NRT smoking cessation aids will reach sales of CZK89 million in 2016.

CATEGORY INDICATORS

  • Table 74 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 75 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 76 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 77 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 78 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 79 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 80 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 81 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

OTC Triptans in the Czech Republic - Category Analysis

TRENDS

  • OTC triptans was only available via prescription in the Czech Republic in 2011 and there are no indications that such products will be made available OTC in the foreseeable future.

Sports Nutrition in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Dynamic growth of sports nutrition reached over the review period slowed down in 2009 as a result of outbreak of financial crisis and its negative impacts. Although value sales of sports nutrition continued to grow at the end of the review period, this growth was slower as consumers were more careful with money and reduced their expenditure. In 2011, sports nutrition increased by 2% in current value terms to reach CZK350 million.

COMPETITIVE LANDSCAPE

  • Sports nutrition is dominated by two domestic companies in 2011, Nutrend DS and Aminostar, which generated combined value share of 62% in 2011. Both producers have long-standing presence on the Czech market and thus are well-established and enjoy strong consumer loyalty and trust. Moreover, success of these two companies lies in their wide range of products on offer and in the fact that their products are considered to be high quality.

PROSPECTS

  • Sports nutrition is expected to have constant value growth of 19% over the forecast period. This dynamic growth will be driven by higher consumption of sports nutrition products which will be supported by rising health and wellness trend. It is also expected that sports nutrition products will gain popularity among increasingly wider group of consumers and therefore the consumer base will increase gradually over the forecast period.

CATEGORY DATA

  • Table 82 Sales of Sports Nutrition: Value 2006-2011
  • Table 83 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 84 Sports Nutrition Company Shares 2007-2011
  • Table 85 Sports Nutrition Brand Shares 2008-2011
  • Table 86 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 87 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Vitamins and dietary supplements had moderate value growth of 1% in 2011. Although this performance was better compared to 2010 when sales of vitamins and dietary supplements stagnated, it was worse compared to review period CAGR. Growth in sales of vitamins and dietary supplements was hampered by consumers trying to save money in the worsened economic situation and higher uncertainty about the future at the end of the review period.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Vitamins and dietary supplements is dominated by two domestic companies, Walmark and Green Swan Pharmaceuticals CR which have combined value share of 55% in 2011.

PROSPECTS

  • Vitamins and dietary supplements is expected to have constant value growth of 12% over the forecast period. Sales of vitamins and dietary supplements will be driven by growing health awareness and interest in healthy lifestyle among Czech consumers over the forecast period. Moreover, it is expected that such drivers as hectic lifestyle and growing pollution of the environment will remain or even deepen over the forecast period and thus will also support sales of these products. In addition, demographic trends such as the ageing population are also expected to boost sales of vitamins and dietary supplements.

CATEGORY DATA

  • Summary 13 Dietary Supplements: Brand Ranking by Positioning 2011
  • Table 88 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 89 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 90 Dietary Supplements by Positioning 2006-2011
  • Table 91 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 92 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 93 Vitamins Brand Shares by Value 2008-2011
  • Table 94 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 95 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 96 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016

Weight Management in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Weight management had dynamic value growth with CAGR of 8% over the review period. Nevertheless, this healthy growth was interrupted by outbreak of financial crisis at the end of this period. In 2009, sales of weight management were positively influenced by launch of OTC obesity brand Alli, which had success among Czech consumers and thus supported overall sales of weight management in this year. However, as negative impacts of worsened economic situation persisted in 2010 and 2011, weight management had much worse performance in these years, with value sales decrease in 2010 and stagnation in 2011.

COMPETITIVE LANDSCAPE

  • Weight management was led by Herbalife Czech Republic with 28% value share in 2011. The company was clear leader of meal replacement slimming with 49% value share and was first in weight loss supplements with 24% value share in 2011. The company’s brand Herbalife Shapeworks has long presence on the Czech market and is thus well-known among consumers.

PROSPECTS

  • Weight management is expected to have constant value growth of 14% over the forecast period. However, the growth of weight management over the forecast period is not expected to be as strong as it was over the review period as it is expected to begin showing signs of saturation. Sales of weight management are predicted to reach CZK484 million by 2016.

CATEGORY DATA

  • Table 97 Sales of Weight Management: Value 2006-2011
  • Table 98 Sales of Weight Management: % Value Growth 2006-2011
  • Table 99 Weight Management Company Shares 2007-2011
  • Table 100 Weight Management Brand Shares 2008-2011
  • Table 101 Forecast Sales of Weight Management: Value 2011-2016
  • Table 102 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in the Czech Republic - Category Analysis

HEADLINES

TRENDS

  • Wound care had decreased by -6% in current value sales in 2011. This drop was driven by first aid kids that had significant jumps in sales in 2010 and 2011 due to legislative changes. In 2010, Ministry of Transport issued new legislation about first aid kits in vehicles. According to this new legislation, all vehicles had to be equipped by new first aid kits from 1 January 2011 (new first aid kits had to contain some new items). As a result, demand for first aid kits increased noticeably in 2010, while in 2011, sales of these products return to their normal levels and thus had a decrease.

COMPETITIVE LANDSCAPE

  • Wound care was led by Hartmann-Rico with 41% value share in 2011. The company was clear leader of all three wound care areas. The company offers wide range of products which are well-established among Czech consumers as quality products. Hartmann-Rico was established in 1991 and is part of the international group Hartmann. The company has three production plants in the Czech Republic.

PROSPECTS

  • It is expected that wound care will register moderate but stable growth with constant value CAGR of 1% over the forecast period. This growth will be higher than that had over the review period as sales will be driven by better economic situation towards the end of this period. At the beginning of the forecast period, value sales will be supported by higher prices of wound care products due to the increase of VAT rate in 2012 and 2013.

CATEGORY DATA

  • Table 103 Sales of Wound Care by Category: Value 2006-2011
  • Table 104 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 105 Wound Care Company Shares by Value 2007-2011
  • Table 106 Wound Care Brand Shares by Value 2008-2011
  • Table 107 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 108 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Aloe
            • Guarana
            • Pumpkin Seed
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
            • Lecithin
            • Other Other Non-Herbal Dietary Supplements
      • Tonics and Bottled Nutritive Drinks
      • Vitamins
        • Multivitamins
        • Single Vitamins
          • Vitamin A
          • Vitamin B
          • Vitamin C
          • Vitamin D
          • Vitamin E
          • Other Single Vitamins
    • Weight Management
      • Meal Replacement Slimming
      • OTC Obesity
      • Slimming Teas
      • Weight Loss Supplements
      • Other Slimming Products
    • Herbal/Traditional Products
      • Herbal/Traditional Analgesics
      • Herbal/Traditional Calming and Sleeping Products
      • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
      • Herbal/Traditional Digestive Remedies
      • Herbal/Traditional Medicated Skin Care
      • Herbal/Traditional Medicinal Teas
      • Herbal/Traditional Smoking Cessation Aids
      • Herbal/Traditional Paediatric Dietary Supplements
      • Herbal/Traditional Dietary Supplements
      • Herbal/Traditional Tonics and Bottled Nutritive Drinks
    • Allergy Care
      • Allergy Eye Care
      • Antihistamines/Allergy Remedies (Systemic)
      • Paediatric Allergy Remedies
      • Topical Allergy Remedies/Antihistamines
    • Paediatric Consumer Health
      • Paediatric Analgesics
        • Paediatric Acetaminophen
        • Paediatric Aspirin
        • Paediatric Combination Products - Analgesics
        • Paediatric Diclofenac
        • Paediatric Dipyrone
        • Paediatric Ibuprofen
        • Paediatric Ketoprofen
        • Paediatric Naproxen
      • Paediatric Cough, Cold and Allergy Remedies
        • Paediatric Allergy Remedies
        • Paediatric Cough/Cold Remedies
      • Paediatric Digestive Remedies
        • Paediatric Diarrhoeal Remedies
        • Paediatric Indigestion and Heartburn Remedies
        • Paediatric Laxatives
        • Paediatric Motion Sickness Remedies
      • Paediatric Medicated Skin Care
      • Nappy (Diaper) Rash Treatments
      • Paediatric Vitamins and Dietary Supplements

Statistics Included

Statistics Included

For each category and subcategory you will receive the following data in Excel format:

From Passport

  • Market sizes
  • Company shares
  • Brand shares
  • Distribution
  • Analysis by format
  • Analysis by positioning
  • Analysis by type
  • Herbal/traditional vs standard
  • Pricing
  • Smoking population - number of adult smokers
  • Smoking prevalence - % of adult population

Market size details:

  • Retail volume
  • Retail volume % growth
  • Retail volume per capita
  • Retail value retail selling price % growth
  • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price % growth
  • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

Methodology

Methodology

Global insight and local knowledge

With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Research Methodology

Our research methods

Each Euromonitor International industry report is based on a core set of research techniques:

Desk research

With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

  • National statistics offices governmental and official sources
  • National and international trade press
  • National and international trade associations
  • Industry study groups and other semi-official sources
  • Company financials and annual reports
  • Broker reports
  • Online databases
  • The financial, business and mainstream press

Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

Store checks

Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

  • Place: We track products in all relevant channels, selective and mass, store and non-store
  • Product: What are innovations in products, pack sizes and formats?
  • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
  • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

Trade survey

Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

Trade surveys allow us to:

  • Fill gaps in available published data per company
  • Generate a consensus view of the size, structure and strategic direction of the category
  • Access year-in-progress data where published sources are out of date
  • Evaluate the experts’ views on current trends and market developments

In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

Company analysis

At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

Forecasts

Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

Data validation

All data is subjected to an exhaustive review process, at country, regional and global levels.

The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

Market analysis

Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

my pages

Want to find out more about this report?

If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!